Study of the Combination Doxorubicin, Interferon Alpha and High-Dose Tamoxifen Treatment for Advanced Hepatocellular Carcinoma
/ 0
- Details
- Category: Vol. 81, March 2013
- Hits: 555
Study of the Combination Doxorubicin, Interferon Alpha and High-Dose Tamoxifen Treatment for Advanced Hepatocellular Carcinoma,EL SAYED M. EL HINDAWY, MOHAMED HEGAZY, TAMER F. YOUSSEF and ASHRAF R. ABO ELFOTOUH
Abstract
Background: A lot of studies showed that high dose tamoxifen may improve the therapeutic efficiency of doxoru-bicin in hepatocellular carcinoma (HCC). Interferon a has also been reported to be effective in treatment of HCC. In this study we assess the addition of interferon-a to high dose tamoxifen and doxorubicin could improve the outcome control of advanced HCC.
Material and Methods: Eligible patients had non—respect-able hepatocellular carcinoma. Large measurable tumor, compensated function, Karnofsky status 60% or more. The patient received oral tamoxifen 40mg/m q.i.d day 1-7; inter-feron subcutaneous injection 3 mu/m2 every other day for 21 day and 1.V doxorubicin 50mg/m at day 4 repeated every 4 weeks.
Results: A total of 45 patients, 40 were eligible, 30 men and 10 women with median age of 50 years. 7 patients had partial remission with a median progression free survival for all patients was 6 month and 1 year survival rate was 11%.